Search Results
Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast Cancer
Dr Tolaney on the Potential Role for Biomarkers in Early-Stage HER2+ Breast Cancer
Current standards for HER2+ early stage breast cancer
Dr. Tolaney on Navigating Adjuvant Therapy in Early-Stage HER2+ Breast Cancer
Case 1: Approach to Early Stage, HER2+ Breast Cancer
Neoadjuvant T-DM1 in Early-Stage HER2+ Breast Cancer
Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast Cancer
Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast Cancer
Dr. Tolaney on Novel Approaches in Treating HER2-Positive Breast Cancer
Neoadjuvant Approaches for Early-Stage HER2+ Breast Cancers
Dr. Tolaney on Activity With Abemaciclib in Patients With HR+/HER2– Breast Cancer
Sara Tolaney, SABCS 2022: Adjuvant paclitaxel and trastuzumab for node-negative HER2+ breast cancer
